Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_assertion type Assertion NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_head.
- NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_provenance.
- NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_assertion evidence source_evidence_literature NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_provenance.
- NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_assertion SIO_000772 11751381 NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_provenance.
- NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_assertion wasDerivedFrom befree-20140225 NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_provenance.
- NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_assertion wasGeneratedBy ECO_0000203 NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_provenance.